World Aquaculture Singapore 2026

June 2-5, 2026

Singapore

EXPERIENCE WITH THE USE OF A LIVE ATTENUATED VACCINE AGAINST SRS

Rolf Hetlelid Olsen*, Marius Karlsen, Martin McAdam, Espen Haaland, Claudia Santander, Vegar Heen, Marianne Bordevik, Glenn Buene, Liv Sandlund, Helen Behzaad

 

PHARMAQ part of Zoetis
Thormøhlensgate 53d, N-5006 Bergen, Norway
rolf.hetlelid-olsen@zoetis.com



Piscirickettsia salmonis causes Salmonid Rickettsial Septicemia (SRS) in farmed salmonid fish globally. In autumn 2024, the disease was diagnosed at several sea sites in Northern Norway. In Chile, SRS has been a significant problem and the main cause of antibiotic use. Comparison of genomes of P. salmonis has shown that there is considerable genetic diversity both within Chile and between Chile, Norway, and other geographies. Vaccines against SRS have been available in the Chilean market for several decades. We present our experience with the live attenuated vaccine ALPHA JECT LiVac SRS (PHARMAQ AS) in Chile, and data on genetic diversity’s impact on cross-protection. Despite genetic differences causing serological variations, vaccinated fish are protected against various P. salmonis strains in laboratory studies. This indicates that vaccination with a live attenuated P. salmonis vaccine has the potential to be a useful tool against SRS outside of Chile as well.